Paper30397355
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.
Imperial MZ and 10 others. Nat Med, 2018. Cited by 276 papers, by iCite.
Cite this record
ConductScience Library. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Papers, record 30397355. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30397355
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antitubercular Agents | Major topic |
| Tuberculosis, Multidrug-Resistant | Major topic |
| Tuberculosis, Pulmonary | Major topic |
| Dose-Response Relationship, Drug | |
| Female | |
| Humans | |
| Kaplan-Meier Estimate | |
| Male | |
| Middle Aged | |
| Phenotype | |
| Risk Factors | |
| Sputum | |
| Treatment Outcome |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 AI104589 | NIAID NIH HHS | United States | R01AI104589 | PubMed and NIH | NIH RePORTER |
| MR/K012126/1 | Medical Research Council | United Kingdom | PubMed | PubMed | |
| R01 AI127300 | NIAID NIH HHS | United States | R01AI127300 | PubMed | NIH RePORTER |
| T32 GM007175 | NIGMS NIH HHS | United States | T32GM007175 | PubMed and NIH | NIH RePORTER |
| 001 | World Health Organization | International | PubMed | PubMed | |
| N01AI095383 | NIH | NIH RePORTER | |||
| R01CA012126 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03941496 | Azacytidine During Anti-tuberculosis Therapy | Background |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 30429542 | Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. | https://conductscience.org/library/papers/30429542 | PubMed |
| Comment in | 30401868 | A stratified approach to tuberculosis treatment. | https://conductscience.org/library/papers/30401868 | PubMed |
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10529902 | Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. | Int J Tuberc Lung Dis | 1999 | https://conductscience.org/library/papers/10529902 | PubMed |
| 2 | 12241657 | Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. | Lancet | 2002 | https://conductscience.org/library/papers/12241657 | PubMed |
| 3 | 15374844 | A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. | Am J Respir Crit Care Med | 2004 | https://conductscience.org/library/papers/15374844 | PubMed |
| 4 | 15533952 | In the treatment of tuberculosis, you get what you pay for... | Am J Respir Crit Care Med | 2004 | https://conductscience.org/library/papers/15533952 | PubMed |
| 5 | 16189810 | Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. | Stat Med | 2005 | https://conductscience.org/library/papers/16189810 | PubMed |
| 6 | 18032770 | Statistics in medicine--reporting of subgroup analyses in clinical trials. | N Engl J Med | 2007 | https://conductscience.org/library/papers/18032770 | PubMed |
| 7 | 19542476 | Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. | Am J Respir Crit Care Med | 2009 | https://conductscience.org/library/papers/19542476 | PubMed |
| 8 | 24518046 | Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen. | Respir Med | 2014 | https://conductscience.org/library/papers/24518046 | PubMed |
| 9 | 25196020 | Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25196020 | PubMed |
| 10 | 25337748 | A four-month gatifloxacin-containing regimen for treating tuberculosis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25337748 | PubMed |
| 11 | 25337749 | High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25337749 | PubMed |
| 12 | 26786954 | Sharing Clinical Trial Data--A Proposal from the International Committee of Medical Journal Editors. | N Engl J Med | 2016 | https://conductscience.org/library/papers/26786954 | PubMed |
| 13 | 27353615 | mHealth for Tuberculosis Treatment Adherence: A Framework to Guide Ethical Planning, Implementation, and Evaluation. | Glob Health Sci Pract | 2016 | https://conductscience.org/library/papers/27353615 | PubMed |
| 14 | 27516382 | Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. | Clin Infect Dis | 2016 | https://conductscience.org/library/papers/27516382 | PubMed |
| 15 | 27776595 | Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis. | Int J Tuberc Lung Dis | 2016 | https://conductscience.org/library/papers/27776595 | PubMed |
| 16 | 28045934 | Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. | PLoS Med | 2017 | https://conductscience.org/library/papers/28045934 | PubMed |
| 17 | 28124478 | Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. | Clin Pharmacol Ther | 2017 | https://conductscience.org/library/papers/28124478 | PubMed |
| 18 | 29326332 | The impact of digital health technologies on tuberculosis treatment: a systematic review. | Eur Respir J | 2018 | https://conductscience.org/library/papers/29326332 | PubMed |
| 19 | 7030377 | Whither short-course chemotherapy? | Br J Dis Chest | 1981 | https://conductscience.org/library/papers/7030377 | PubMed |
Cited by218
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 276 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42971965 | Risk stratification for MDR/RR-TB: a comprehensive integrated patient-level analysis from TB programs and contemporary clinical trials. | Nat Commun | 2026 | https://conductscience.org/library/papers/42971965 | PubMed |
| 42935866 | Dried blood spot IP-10 as a biomarker of tuberculosis severity and treatment responses: results from a phase IIb trial of adjunctive acetylsalicylic acid and ibuprofen. | Front Immunol | 2026 | https://conductscience.org/library/papers/42935866 | PubMed |
| 42898291 | Prognostic utility of immune biomarkers for identifying individuals at risk of unfavourable treatment outcomes in pulmonary tuberculosis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898291 | PubMed |
| 42755735 | Treatment shortening and relapse control in drug-susceptible pulmonary tuberculosis: a network meta-analysis of randomized trials. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42755735 | PubMed |
| 42675628 | Single-Cell Immune Profiling Suggests Non-Classical Monocyte Is Associated Immunodepression in Tuberculosis Treatment Non-Responders. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/42675628 | PubMed |
| 42638666 | Ending tuberculosis: challenges and opportunities. | Front Tuberc | 2024 | https://conductscience.org/library/papers/42638666 | PubMed |
| 42638631 | An integrated psycho-social intervention to improve self-efficacy toward TB treatment uptake and infection prevention among patients and family caregivers: a multicentric implementation research study protocol. | Front Tuberc | 2026 | https://conductscience.org/library/papers/42638631 | PubMed |
| 42582131 | The PATHFAST TB LAM Ag assay: a validated protocol for quantitative tuberculosis treatment monitoring. | Front Antibiot | 2026 | https://conductscience.org/library/papers/42582131 | PubMed |
| 42576151 | Applying a Pharmacometrics-Enabled Machine Learning Analysis to Predict 2-Month Culture Conversion Using Phase 2a Data in a Tuberculosis Clinical Trial. | Clin Transl Sci | 2026 | https://conductscience.org/library/papers/42576151 | PubMed |
| 42477612 | Exposure to the four first-line anti-tuberculosis drugs and treatment outcomes: a target trial emulation study in Ghana. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/42477612 | PubMed |
| 42369478 | Within-host pathogen population diversity predicts treatment response in Tuberculosis. | medRxiv | 2026 | https://conductscience.org/library/papers/42369478 | PubMed |
| 42245132 | Transformer-based ensemble framework for tuberculosis treatment response prediction: multi-omics integration with clinical-grade performance. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/42245132 | PubMed |
| 42198395 | Is Short Therapy an Appropriate Regimen for Children and Young Adolescents with Drug-Susceptible Tuberculosis? | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42198395 | PubMed |
| 42182461 | In vitro dormancy models improve ability to predict treatment response in severe marmoset tuberculosis lesions. | bioRxiv | 2026 | https://conductscience.org/library/papers/42182461 | PubMed |
| 42062935 | Socio-ecological vulnerability subgroups predict adherence and treatment outcomes in multidrug-resistant tuberculosis and HIV: a latent class analysis. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/42062935 | PubMed |
| 41994124 | Exposure to the Four First-Line Anti-Tuberculosis Drugs and Treatment Outcomes: A Target Trial Emulation Study in Ghana. | Res Sq | 2026 | https://conductscience.org/library/papers/41994124 | PubMed |
| 41989328 | Tuberculosis Disease Severity Assessment Using Clinical Variables and Radiology Enabled by Artificial Intelligence. | J Infect Dis | 2026 | https://conductscience.org/library/papers/41989328 | PubMed |
| 41946910 | Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation. | EMBO Mol Med | 2026 | https://conductscience.org/library/papers/41946910 | PubMed |
| 41849373 | Effectiveness of routine tuberculosis education in a high-burden setting: A prospective observational cohort study. | PLoS One | 2026 | https://conductscience.org/library/papers/41849373 | PubMed |
| 41800241 | Exploring Host-driven Immunopathological Factors Developing Severe Tuberculosis: Insights from Comparative Mouse Models. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/41800241 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30397355
GET https://conductscience.org/api/papers/v1/30397355/cited_by?page=2